Recursion Pharmaceuticals (NasdaqGS:RXRX) reports positive clinical proof of concept for REC-4881 in familial adenomatous ...

In February 2026, Recursion Pharmaceuticals reported fourth-quarter 2025 revenue of US$35.54 million, sharply higher than a year earlier, while its quarterly net loss narrowed to US$108.12 million and ...

Recursion Pharmaceuticals (NasdaqGS:RXRX) reports its first AI enabled clinical proof of concept in familial adenomatous polyposis. The company advances five clinical programs, signaling broader use ...

Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI-driven biological insight to meaningful patient outcomes; multiple ...

Recursion Pharmaceuticals, Inc. (RXRX) has been making great progress lately in being able to advance its pipeline. That's because it has been advancing two clinical candidates in phase 2 studies. It ...

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the stocks on Jim Cramer’s radar recently. When a caller asked about the stock during the lightning round, Cramer stated: “I don’t know. It’s ...